Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY).
周三，罗氏控股股份公司（场外交易代码：RHHBY）与隆沙集团有限公司（场外交易代码：LZAGF）（场外交易代码：LZAGY）签订了最终协议。
Under the agreement, Lonza will acquire the Genentech manufacturing facility in Vacaville, California, for $1.2 billion in conjunction with a manufacturing agreement and related quality services and warehousing.
根据该协议，Lonza将以12亿美元的价格收购位于加利福尼亚州瓦卡维尔的基因泰克制造工厂，同时收购制造协议以及相关的优质服务和仓储。
Under the terms of the agreement, Lonza will offer approximately 750 Genentech employees at the Vacaville facility employment, and the products currently produced at the site by Roche will continue to be supplied by Lonza for a transition period.
根据协议条款，隆沙将为瓦卡维尔工厂的大约750名基因泰克员工提供就业机会，而罗氏目前在该工厂生产的产品将在过渡期内继续由龙沙提供。
The acquisition will increase Lonza's large-scale biologics manufacturing capacity. The Vacaville (US) facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics manufacturing sites in the world by volume.
此次收购将提高Lonza的大规模生物制剂制造能力。瓦卡维尔（美国）工厂目前的生物反应器总容量约为33万升，是世界上体积最大的生物制剂生产基地之一。
Lonza plans to invest approximately CHF 500 million in additional Capex to upgrade the Vacaville (US) facility and enhance capabilities to satisfy demand for the next generation of mammalian biologics therapies.
Lonza计划投资约5亿瑞士法郎的额外资本支出，以升级瓦卡维尔（美国）的设施并增强能力，以满足对下一代哺乳动物生物制剂疗法的需求。
The products currently manufactured at the site by Roche will be supplied by Lonza, with committed volumes over the medium term, phasing out over time as the site transitions to serve alternative customers.
罗氏目前在该工厂生产的产品将由Lonza提供，承诺在中期内批量生产，随着工厂过渡到为替代客户提供服务，将逐步淘汰。
As the transaction is expected to be accretive to sales growth, Lonza has updated its mid-term guidance for 2024–2028.
由于该交易预计将促进销售增长，Lonza更新了其2024-2028年的中期指导。
Its sales growth range was set at 11–13% CAGR in CER and has now been updated to 12 – 15%.
按恒定汇率计算，其销售增长区间设定为11-13％的复合年增长率，现已更新至12-15％。
Mid-term guidance for core EBITDA margin and ROIC remains unchanged.
核心息税折旧摊销前利润率和投资回报率的中期指导保持不变。
The transaction is expected to close by H2 2024.
该交易预计将于2024年下半年完成。